Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

HCW Biologics (HCWB) EBIT (2021 - 2025)

Historic EBIT for HCW Biologics (HCWB) over the last 5 years, with Q3 2025 value amounting to -$3.3 million.

  • HCW Biologics' EBIT rose 1065.03% to -$3.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$11.9 million, marking a year-over-year increase of 6792.92%. This contributed to the annual value of -$29.5 million for FY2024, which is 1463.03% down from last year.
  • Latest data reveals that HCW Biologics reported EBIT of -$3.3 million as of Q3 2025, which was up 1065.03% from -$3.5 million recorded in Q2 2025.
  • In the past 5 years, HCW Biologics' EBIT ranged from a high of -$1.9 million in Q1 2022 and a low of -$15.1 million during Q2 2024
  • Its 5-year average for EBIT is -$4.9 million, with a median of -$3.7 million in 2024.
  • Per our database at Business Quant, HCW Biologics' EBIT plummeted by 23557.12% in 2024 and then soared by 7711.37% in 2025.
  • Quarter analysis of 5 years shows HCW Biologics' EBIT stood at -$3.1 million in 2021, then crashed by 82.08% to -$5.7 million in 2022, then crashed by 90.01% to -$10.8 million in 2023, then surged by 70.56% to -$3.2 million in 2024, then fell by 3.83% to -$3.3 million in 2025.
  • Its last three reported values are -$3.3 million in Q3 2025, -$3.5 million for Q2 2025, and -$2.0 million during Q1 2025.